IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by AE Wealth Management LLC

AE Wealth Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 10.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,362 shares of the medical research company’s stock after purchasing an additional 1,431 shares during the quarter. AE Wealth Management LLC’s holdings in IQVIA were worth $3,248,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Versant Capital Management Inc lifted its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter worth $27,000. Rise Advisors LLC acquired a new stake in shares of IQVIA during the first quarter worth $31,000. Riverview Trust Co purchased a new stake in shares of IQVIA in the first quarter valued at $32,000. Finally, International Assets Investment Management LLC acquired a new position in IQVIA in the second quarter valued at $32,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of several recent analyst reports. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Evercore ISI boosted their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Barclays increased their target price on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. boosted their price target on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $267.00.

IQVIA Stock Performance

IQVIA stock opened at $242.12 on Monday. The firm has a market capitalization of $44.14 billion, a PE ratio of 33.08, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The stock’s 50 day moving average price is $240.60 and its 200 day moving average price is $233.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.